PRA Health Sciences pioneers connecting clinical trial patients with their real-world data with Synoma
13 mai 2021 16h02 HE
|
PRA Health Sciences, Inc.
RALEIGH, N.C., May 13, 2021 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ: PRAH) announced today an innovative tokenization solution using Synoma®, PRA’s proprietary technology that allows...
Real-World Evidence (RWE) Solutions Market Worth $1.64 Billion by 2024, Growing at a CAGR of 15% from 2019- Market Opportunity Analysis and Industry Forecasts by Meticulous Research®
23 juin 2020 13h19 HE
|
Meticulous Market Research Pvt. Ltd.
London, June 23, 2020 (GLOBE NEWSWIRE) -- With the growing need to achieve better value for healthcare, the importance of real-world evidence (RWE) as a decision-making tool and an important part of...
Tempus Launches COVID-19-Specific Clinical and Research Initiatives for Oncology
30 mai 2020 10h30 HE
|
Tempus
CHICAGO, May 30, 2020 (GLOBE NEWSWIRE) -- Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, introduced a series of...
Syapse, FDA, and Advocate Aurora Health to Present Pneumonitis Safety Data in Plenary Talk at AACR Virtual Meeting
27 avr. 2020 08h00 HE
|
Syapse
Data presented demonstrates that patients with a past medical history of pneumonitis had a higher incidence of treatment associated pneumonitis in both clinical trial and real-world data AACR Virtual...
Syapse Appoints Dr. Thomas D. Brown as Chief Medical Officer
16 oct. 2019 08h26 HE
|
Syapse
SAN FRANCISCO, Oct. 16, 2019 (GLOBE NEWSWIRE) -- Syapse today announced the appointment of Thomas D. Brown, MD, MBA as its first Chief Medical Officer. Dr. Brown, an internationally renowned...
Syapse Appoints Fletcher Payne as Chief Financial Officer
10 sept. 2019 08h00 HE
|
Syapse
SAN FRANCISCO, Sept. 10, 2019 (GLOBE NEWSWIRE) -- Syapse, a company accelerating precision medicine through insights derived from its global health system network, today announced that Fletcher...
Syapse Announces Research Collaboration with the FDA Focused on the Regulatory Use of Real-World Evidence
14 août 2019 06h00 HE
|
Syapse
SAN FRANCISCO, Aug. 14, 2019 (GLOBE NEWSWIRE) -- Syapse and the U.S. Food and Drug Administration (FDA) Oncology Center of Excellence (OCE) have signed a multi-year Research Collaboration Agreement...
Seoul National University Hospital and Syapse Sign Multi-Year Renewal Agreement to Expand Access to Precision Medicine in South Korea
06 août 2019 08h00 HE
|
Syapse
Syapse and SNUH will work together to build Asia’s first learning health network of real-world data derived from the region’s leading precision oncology hospitals Co-hosted symposium of East Asian...
UPDATE -- Tempus Announces $200 Million in Series F Financing
30 mai 2019 09h02 HE
|
Tempus
CHICAGO, May 30, 2019 (GLOBE NEWSWIRE) -- Tempus, a leading technology company advancing precision medicine through the collection and analysis of molecular and clinical data, announced today an...
Tempus Announces $200 Million in Series F Financing
30 mai 2019 06h00 HE
|
Tempus
CHICAGO, May 30, 2019 (GLOBE NEWSWIRE) -- Tempus, a leading technology company advancing precision medicine through the collection and analysis of molecular and clinical data, announced today an...